Journal of Clinical Oncology, Vol 12, 2187-2192, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Secondary malignancies after bone marrow transplantation in adults

R Lowsky, J Lipton, G Fyles, M Minden, J Meharchand, I Tejpar, H Atkins, S Sutcliffe and H Messner
Department of Medicine, Princess Margaret Hospital, Toronto, Ontario, Canada.

PURPOSE: The records of 557 consecutive adult recipients of allogeneic- related and -unrelated and syngeneic bone marrow transplants (BMTs) were reviewed to determine the incidence of secondary cancers. PATIENTS AND METHODS: Four hundred fifty-six patients were transplanted for acute lymphocytic leukemia (ALL; n = 79), acute myelogenous leukemia (AML; n = 182), and chronic myelogenous leukemia (CML; n = 195); 42 patients were transplanted for aplastic anemia (AA) and 59 for a variety of other hematologic and nonhematologic disorders, malignant and nonmalignant. Conditioning regimens included high-dose chemotherapy with or without total-body irradiation (TBI). Statistical analyses determined the cumulative incidence of developing a secondary cancer and elucidated the associated risk factors. Complete records (1 to 24 years of follow-up) on all patients were available. RESULTS: Nine patients developed 10 secondary cancers for a cumulative actuarial risk of 12% (95% confidence interval [CI], 4.3 to 23.0) 11 years after transplant. The age-adjusted incidence of secondary cancer was 4.2 times higher than that of primary cancer in the general population. Eight of the 10 were epithelial in origin and three were cutaneous. TBI and acute graft-versus-host disease (GVHD) with a severity > or = grade II were associated with the development of any secondary cancer. On the other hand, chronic GVHD was a risk factor only for the development of secondary skin neoplasms. CONCLUSION: Adult recipients of BMT face a significant risk of developing a secondary malignancy. Their risk is similar to that of other patients with hematologic malignancies who are treated with chemoradiotherapy only. Epithelial tumors, rather than the more commonly reported Epstein-Barr virus (EBV)-associated lymphomas, were most common. The fact that we did not routinely use T-cell- depleted marrow grafts nor anti-T-cell immunoglobulin for the treatment of acute GVHD may explain this variance.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Cohen, A. Rovelli, D. F. Merlo, M. T. van Lint, E. Lanino, D. Bresters, M. Ceppi, V. Bocchini, A. Tichelli, and G. Socie Risk for Secondary Thyroid Carcinoma After Hematopoietic Stem-Cell Transplantation: An EBMT Late Effects Working Party Study J. Clin. Oncol., June 10, 2007; 25(17): 2449 - 2454. [Abstract] [Full Text] [PDF]

				R. E. Curtis, C. Metayer, J. D. Rizzo, G. Socie, K. A. Sobocinski, M. E. D. Flowers, W. D. Travis, L. B. Travis, M. M. Horowitz, and H. J. Deeg Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study Blood, May 15, 2005; 105(10): 3802 - 3811. [Abstract] [Full Text] [PDF]

				K. C. Oeffinger and M. M. Hudson Long-term Complications Following Childhood and Adolescent Cancer: Foundations for Providing Risk-based Health Care for Survivors CA Cancer J Clin, July 1, 2004; 54(4): 208 - 236. [Abstract] [Full Text] [PDF]

				H. J. Kolb, G. Socie, T. Duell, M. T. Van Lint, A. Tichelli, J. F. Apperley, E. Nekolla, P. Ljungman, N. Jacobsen, M. van Weel, et al. Malignant Neoplasms in Long-Term Survivors of Bone Marrow Transplantation Ann Intern Med, November 16, 1999; 131(10): 738 - 744. [Abstract] [Full Text] [PDF]

				A. S. Freedman, D. Neuberg, P. Mauch, R. J. Soiffer, K. C. Anderson, D. C. Fisher, R. Schlossman, E. P. Alyea, T. Takvorian, H. Jallow, et al. Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma Blood, November 15, 1999; 94(10): 3325 - 3333. [Abstract] [Full Text] [PDF]

				S. Aractingi and O. Chosidow Cutaneous Graft-versus-Host Disease Arch Dermatol, May 1, 1998; 134(5): 602 - 612. [Abstract] [Full Text] [PDF]

				H. J. Deeg and G. Socie Malignancies After Hematopoietic Stem Cell Transplantation: Many Questions, Some Answers Blood, March 15, 1998; 91(6): 1833 - 1844. [Full Text] [PDF]

				M. de Lima, S. S. Strom, M. Keating, H. Kantarjian, S. Pierce, S. O'Brien, E. Freireich, and E. Estey Implications of Potential Cure in Acute Myelogenous Leukemia: Development of Subsequent Cancer and Return to Work Blood, December 15, 1997; 90(12): 4719 - 4724. [Abstract] [Full Text] [PDF]

				R. E. Curtis, P. A. Rowlings, H. J. Deeg, D. A. Shriner, G. Socie, L. B. Travis, M. M. Horowitz, R. P. Witherspoon, R. N. Hoover, K. A. Sobocinski, et al. Solid Cancers after Bone Marrow Transplantation N. Engl. J. Med., March 27, 1997; 336(13): 897 - 904. [Abstract] [Full Text] [PDF]